Skip to content

Drugs and Alcohol Today

ISSN 1745-9265

8 papers in the library · 125 citations · publishing 2004-2020

Papers

Psychedelic substance use in the Reddit psychonaut community. A qualitative study on motives and modalities

Drugs and Alcohol Today August 3, 2020 Jani Pestana, Franca Beccaria, Enrico Petrilli 41 citations

Psychonauts on Reddit use psychedelic substances for self-knowledge, self-investigation, self-medication, artistic expression, curiosity, and recreation. They emphasize preparation, set and setting, integration, careful dosing, and sharing information through research and trip reports—practices aligned with responsible drug use. These findings highlight evolving norms in non-medical, non-rave Western psychedelic use.

MDMA powder, pills and crystal: the persistence of ecstasy and the poverty of policy

Drugs and Alcohol Today April 13, 2009 Zoë Smith, Karenza Moore, Fiona Measham 34 citations

Ecstasy (MDMA) use in Britain has declined since 2001 according to the British Crime Survey, but a new form of MDMA powder or crystal has emerged as a 'premium' product, rebranded in response to user dissatisfaction with poor-quality pills. These changes occurred within a policy context that prioritized the drugs-crime relationship through coercive treatment of problem drug users and a focus on binge drinking, leading to a reduction in information, support, and treatment for ecstasy users since the mid-1990s Safer Dancing harm reduction model.

Ibogaine therapy in the treatment of opiate dependency

Drugs and Alcohol Today December 2, 2010 Peter Brackenridge 6 citations

Ibogaine therapy, combined with psychoanalytic psychotherapy, offers a viable alternative to mainstream opiate addiction treatment. Ibogaine's addiction-arresting and fast-acting properties complement the slow, thoughtful conversation of psychotherapy, creating a novel approach to a difficult condition. Safer than methadone, ibogaine use is increasing worldwide and became a prescription medication in New Zealand in 2010. Howard Lotsof, who discovered ibogaine's anti-addictive properties 47 years earlier, devoted his life to improving access before his death in January 2010. This paper explores how these two approaches differ from other treatment modalities.

The visionary cure of the addiction war? Ibogaine: social context, subcultural identity, and implications for drug policy

Drugs and Alcohol Today June 17, 2011 James Rodger 5 citations

Ibogaine, a hallucinogenic alkaloid from the West African plant Tabernanthe iboga, is used in an underground treatment scene for alcohol and substance dependence. The paper draws on comparative ethnography of magicoreligious iboga use in West Africa and contemporary accounts of ibogaine addiction treatment, contextualizing these within neurobiology and anthropology. The medicine's impact on craving, withdrawal, and psycho-spiritual insight may validate the hope it generates. Successful treatments appear to respect but transform subcultural meanings and identities while promoting realism and psychosocial integration. The scale of underground use demands urgent funding for research to optimize safety.

A brief history and motivation of an entheogenic chemist

Drugs and Alcohol Today July 1, 2007 Casey Hardison 2 citations

The text recounts the 2004 arrest of Casey Hardison for producing psychedelic drugs (LSD, 2C-B, DMT) and argues that authorities never asked about his motivations, assuming greed was the reason. Hardison claimed his actions were a stand for cognitive liberty and personal transformation through expanded consciousness, but the judge dismissed this as a ruse. The author presents Hardison's perspective as a committed defense of cognitive liberty and a vision of a world where people understand the connection between individuality and unity.

Ibogaine ‐ poison or panacea?

Drugs and Alcohol Today November 1, 2004 Gary Hayes

Ibogaine is described as both a potential miracle cure for addictions—with reports of up to 90% effectiveness—and a substance linked to violent reactions and increased overdose risk. This overview examines its promise as an addiction treatment, drawing on interviews with those who administer and use it. It also explores why so little research has been conducted in the UK to establish its safety, and points to political and commercial reluctance to investigate its potential.